Stay updated on Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.

Latest updates to the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1.0%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check35 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check42 days agoChange DetectedThe webpage has updated its date references, adding two new dates in May 2025 while removing two older dates from February 2022.SummaryDifference0.8%
- Check64 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check78 days agoChange DetectedThe page has been updated to include new information about a clinical trial for metastatic renal cell cancer, including the addition of a new principal investigator and collaborators, while significant details about the trial's objectives and treatment methods have been removed.SummaryDifference45%
Stay in the know with updates to Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.